JP2015500811A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015500811A5 JP2015500811A5 JP2014544968A JP2014544968A JP2015500811A5 JP 2015500811 A5 JP2015500811 A5 JP 2015500811A5 JP 2014544968 A JP2014544968 A JP 2014544968A JP 2014544968 A JP2014544968 A JP 2014544968A JP 2015500811 A5 JP2015500811 A5 JP 2015500811A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- amino acid
- acid sequence
- seq
- vid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037865 fusion proteins Human genes 0.000 claims 52
- 108020001507 fusion proteins Proteins 0.000 claims 52
- 125000003275 alpha amino acid group Chemical group 0.000 claims 26
- 239000000203 mixture Substances 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 108060003951 Immunoglobulin Proteins 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 4
- 102000018358 immunoglobulin Human genes 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 230000024203 complement activation Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 102000058223 human VEGFA Human genes 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000016550 Complement Factor H Human genes 0.000 claims 1
- 108010053085 Complement Factor H Proteins 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000011325 dry age related macular degeneration Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 102000034356 gene-regulatory proteins Human genes 0.000 claims 1
- 108091006104 gene-regulatory proteins Proteins 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161629932P | 2011-12-01 | 2011-12-01 | |
| US61/629,932 | 2011-12-01 | ||
| PCT/US2012/067489 WO2013082563A1 (en) | 2011-12-01 | 2012-11-30 | Protein inhibitors to complement and vegf pathways and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017087530A Division JP2017189167A (ja) | 2011-12-01 | 2017-04-26 | 補体経路およびｖｅｇｆ経路に対するタンパク質インヒビターおよびそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015500811A JP2015500811A (ja) | 2015-01-08 |
| JP2015500811A5 true JP2015500811A5 (enExample) | 2016-01-21 |
| JP6138815B2 JP6138815B2 (ja) | 2017-05-31 |
Family
ID=48536152
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014544968A Active JP6138815B2 (ja) | 2011-12-01 | 2012-11-30 | 補体経路およびｖｅｇｆ経路に対するタンパク質インヒビターおよびそれらの使用方法 |
| JP2017087530A Pending JP2017189167A (ja) | 2011-12-01 | 2017-04-26 | 補体経路およびｖｅｇｆ経路に対するタンパク質インヒビターおよびそれらの使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017087530A Pending JP2017189167A (ja) | 2011-12-01 | 2017-04-26 | 補体経路およびｖｅｇｆ経路に対するタンパク質インヒビターおよびそれらの使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9988611B2 (enExample) |
| EP (1) | EP2785744B1 (enExample) |
| JP (2) | JP6138815B2 (enExample) |
| CN (2) | CN110078831A (enExample) |
| AU (1) | AU2012318288B2 (enExample) |
| BR (1) | BR112014013205A2 (enExample) |
| CA (1) | CA2857168C (enExample) |
| DK (1) | DK2785744T3 (enExample) |
| ES (1) | ES2651521T3 (enExample) |
| WO (1) | WO2013082563A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110078831A (zh) | 2011-12-01 | 2019-08-02 | 圆祥生命科技股份有限公司 | 补体和vegf途径的蛋白质抑制剂及其使用方法 |
| CN104721820A (zh) * | 2013-12-24 | 2015-06-24 | 信达生物制药(苏州)有限公司 | 双特异性单克隆抗体在治疗葡萄膜炎中的用途 |
| LT3110434T (lt) * | 2014-02-24 | 2018-12-27 | Takeda Gmbh | Sulieti uti baltymai |
| CN106459218B (zh) * | 2014-03-24 | 2021-03-02 | 宜明昂科生物医药技术（上海）有限公司 | 新的重组双功能融合蛋白、其制剂和用途 |
| US10155983B2 (en) | 2014-03-31 | 2018-12-18 | Machaon Diagnostics, Inc. | Method of diagnosis of complement-mediated thrombotic microangiopathies |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| CN105327346B (zh) * | 2014-08-07 | 2019-10-18 | 信达生物制药(苏州)有限公司 | 一种单克隆抗体在治疗银屑病中的应用 |
| CN104940926B (zh) | 2014-09-25 | 2017-09-22 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
| CN105435222B (zh) | 2014-09-25 | 2018-05-29 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
| CN106084062B (zh) * | 2015-04-28 | 2021-04-02 | 荣昌生物制药（烟台）有限公司 | 桥连的双特异性融合蛋白 |
| WO2017001990A1 (en) | 2015-06-28 | 2017-01-05 | Allgenesis Biotherapeutics Inc. | Fusion proteins for inhibiting angiogenesis |
| EP3377101A4 (en) * | 2015-11-19 | 2019-08-07 | Zhuhai Tairuishang Biopharm Ltd. | VEGF BINDING METHODS AND COMPOSITIONS |
| CN106890313A (zh) * | 2015-12-18 | 2017-06-27 | 信达生物制药(苏州)有限公司 | 用于治疗病理性近视的药物 |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| WO2017114401A1 (zh) * | 2015-12-31 | 2017-07-06 | 江苏匡亚生物医药科技有限公司 | 具有补体调节活性的重组补体因子h-免疫球蛋白融合蛋白及其制备方法与应用 |
| KR101685532B1 (ko) * | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
| EA037848B1 (ru) * | 2016-07-14 | 2021-05-27 | Общество С Ограниченной Ответственностью "Биохимический Агент" | Гибридный белок, полинуклеотид, генетическая конструкция, продуцент, препарат для регенерации хряща (варианты) |
| CA3026892A1 (en) * | 2017-05-10 | 2018-11-15 | Wellstat Immunotherapeutics, Llc | Enveloped virus resistant to complement inactivation for the treatment of cancer |
| CN107602702A (zh) * | 2017-09-22 | 2018-01-19 | 生标（上海）医疗器械科技有限公司 | 一种同时靶向人p185和血管内皮生长因子的抗体及其应用 |
| GB201800620D0 (en) * | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| PT3793586T (pt) * | 2018-05-16 | 2024-07-10 | Csl Ltd | Variantes do receptor solúvel do complemento de tipo 1 e sua utilização |
| WO2020037309A1 (en) * | 2018-08-17 | 2020-02-20 | Trican Biotechnology Co., Ltd. | Anti-angiogenesis fusion protein and uses thereof |
| EP3863657A4 (en) * | 2018-10-12 | 2022-07-20 | Trican Biotechnology Co., Ltd | BIFUNCTIONAL FUSION PROTEINS AND USES THEREOF |
| GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| CN111378044B (zh) * | 2018-12-28 | 2022-07-15 | 长春金赛药业有限责任公司 | 抗体融合蛋白、制备方法及其应用 |
| CN111423512B (zh) * | 2019-01-10 | 2024-01-05 | 北京比洋生物技术有限公司 | 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 |
| WO2020213004A1 (en) * | 2019-04-13 | 2020-10-22 | National Centre For Cell Science | Daf-mcp chimeric proteins, process to manufacture the same and use of the chimeric protein for treating pathological conditions involving the complement system |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021076991A1 (en) * | 2019-10-17 | 2021-04-22 | Annexon, Inc. | Compositions and methods for treating blood disorders |
| CN114867489A (zh) * | 2019-12-24 | 2022-08-05 | 信达生物制药(苏州)有限公司 | 融合蛋白在治疗年龄相关性黄斑变性中的应用 |
| JP2023517403A (ja) * | 2020-03-21 | 2023-04-26 | ラリクス・バイオサイエンス・リミテッド・ライアビリティ・カンパニー | Ａｃｅ２および補体経路の二重特異性および三重特異性機能性分子ならびにその使用 |
| CN115803009A (zh) | 2020-05-08 | 2023-03-14 | 瑞泽恩制药公司 | 用于治疗眼病和癌症的vegf阱和微阱及方法 |
| US20230242633A1 (en) * | 2020-07-07 | 2023-08-03 | Kanaph Therapeutics Inc. | Fusion protein including complement pathway inhibitor and angiogenesis inhibitor and use thereof |
| AU2021362770A1 (en) * | 2020-10-16 | 2022-12-08 | Gyroscope Therapeutics Limited | Nucleic acid encoding an anti-VEGF entity and a negative complement regulator and uses thereof for the treatment of age-related macular degeneration |
| CN113041360A (zh) * | 2021-04-01 | 2021-06-29 | 深圳廷美奥生物技术有限公司 | 一种用于治疗年龄相关性黄斑变性的药物 |
| EP4386009A4 (en) * | 2021-08-09 | 2025-05-14 | Yuanpu Biotechnology (Wuhan) Co., Ltd. | BISPECIFIC FUSION POLYPEPTIDE AND USE THEREOF |
| TW202328211A (zh) * | 2021-11-19 | 2023-07-16 | 圓祥生技股份有限公司 | 針對補體途徑的雙功能融合蛋白、其醫藥組成物及其治療或預防補體相關疾病的用途 |
| KR20230105972A (ko) * | 2022-01-05 | 2023-07-12 | 주식회사 카나프테라퓨틱스 | 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도 |
| CN116675777B (zh) * | 2022-02-23 | 2025-07-08 | 中山光度生物医药有限公司 | 包含补体抑制结构域的多特异性配体结合分子及其用途 |
| GB202203627D0 (en) | 2022-03-16 | 2022-04-27 | Univ Manchester | Agents for treating complement-related disorders |
| US20250257106A1 (en) | 2022-04-11 | 2025-08-14 | Longbio Pharma (Suzhou) Co., Ltd. | Complement-inhibiting hybrid protein |
| US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
| CN118005802A (zh) | 2022-11-10 | 2024-05-10 | 天辰生物医药(苏州)有限公司 | 补体抑制杂合蛋白突变体及其抗体融合蛋白 |
| CN120476152A (zh) * | 2022-11-28 | 2025-08-12 | 深圳欧科健生物医药科技有限公司 | C5/vegf双特异性结合分子 |
| KR20250163297A (ko) | 2023-01-05 | 2025-11-20 | 컴플리먼트 테라퓨틱스 리미티드 | 보체 질환 치료제 및 치료방법 |
| WO2025021112A1 (zh) * | 2023-07-24 | 2025-01-30 | 佳吾益(北京)科技有限公司 | 开发mhc新抗原的工程化细胞 |
| WO2025109172A1 (en) * | 2023-11-24 | 2025-05-30 | Universität Ulm | Complement modulator |
| EP4559472A1 (en) * | 2023-11-24 | 2025-05-28 | Universität Ulm | Complement modulator |
| CN117467025B (zh) * | 2023-12-28 | 2024-04-16 | 上海鼎新基因科技有限公司 | 一种抗vegf和补体双功能融合蛋白及其应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| IL89790A (en) * | 1988-04-01 | 2002-05-23 | Johns Hopking University | Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| CA2171953C (en) * | 1993-09-24 | 2003-02-04 | John P. Atkinson | Modified truncated complement system regulators |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| GB9614871D0 (en) * | 1996-07-15 | 1996-09-04 | Smithkline Beecham Plc | Compounds |
| JP4723140B2 (ja) | 1999-06-08 | 2011-07-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 改善された薬物動態特性を有する改変キメラポリペプチド |
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| AU7902401A (en) * | 2000-08-01 | 2002-02-13 | Amgen Inc | C3b/c4b complement receptor-like molecules and uses thereof |
| MXPA03007186A (es) * | 2001-02-09 | 2005-07-01 | Human Genome Sciences Inc | Receptor de quimiocina de proteina g humana (ccr5) hdgnr10. |
| EP2292259A3 (en) | 2002-11-15 | 2011-03-23 | MUSC Foundation For Research Development | Complement receptor 2 targeted complement modulators |
| US20070155663A1 (en) | 2003-03-24 | 2007-07-05 | Rudolf Richter | Use of chemokine receptor agonists for stem cell transplantation |
| US20070148170A1 (en) | 2005-10-03 | 2007-06-28 | Desjarlais John R | Fc Variants With Optimized Fc Receptor Binding Properties |
| US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| CA2621047A1 (en) | 2005-02-02 | 2006-08-24 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a vegf inhibitor |
| CN101384614A (zh) * | 2005-08-15 | 2009-03-11 | 加利福尼亚大学董事会 | Vegf活化的fas配体 |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| JP5345849B2 (ja) | 2005-10-08 | 2013-11-20 | ポテンシア ファーマシューティカルズ， インコーポレイテッド | 眼の障害のためのコンプスタチンおよびそのアナログ |
| WO2007047995A2 (en) * | 2005-10-21 | 2007-04-26 | Catalyst Biosciences, Inc. | Modified proteases that inhibit complement activation |
| AU2007261315B2 (en) | 2006-06-21 | 2012-10-25 | Musc Foundation For Research Development | Targeting complement factor H for treatment of diseases |
| WO2008048675A2 (en) * | 2006-10-20 | 2008-04-24 | Celldex Therapeutics, Inc. | Treatment for age-related macular degeneration and other diseases of the eye |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| CN102317320A (zh) * | 2008-12-11 | 2012-01-11 | 韩国科学技术院 | 能够结合于VEGF-A和TNF-α的融合蛋白 |
| EP2417263B1 (en) * | 2009-04-09 | 2015-09-23 | ProteoVec Holding L.L.C. | Production of proteins using transposon-based vectors |
| CN102219859B (zh) * | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | 拮抗血管新生诱导因子的融合蛋白及其用途 |
| CN110078831A (zh) | 2011-12-01 | 2019-08-02 | 圆祥生命科技股份有限公司 | 补体和vegf途径的蛋白质抑制剂及其使用方法 |
-
2012
- 2012-11-30 CN CN201910007111.8A patent/CN110078831A/zh active Pending
- 2012-11-30 CA CA2857168A patent/CA2857168C/en active Active
- 2012-11-30 BR BR112014013205-4A patent/BR112014013205A2/pt not_active IP Right Cessation
- 2012-11-30 WO PCT/US2012/067489 patent/WO2013082563A1/en not_active Ceased
- 2012-11-30 CN CN201280068781.7A patent/CN104159926B/zh active Active
- 2012-11-30 ES ES12853600.0T patent/ES2651521T3/es active Active
- 2012-11-30 JP JP2014544968A patent/JP6138815B2/ja active Active
- 2012-11-30 EP EP12853600.0A patent/EP2785744B1/en active Active
- 2012-11-30 US US14/362,109 patent/US9988611B2/en active Active
- 2012-11-30 DK DK12853600.0T patent/DK2785744T3/da active
- 2012-11-30 AU AU2012318288A patent/AU2012318288B2/en active Active
-
2017
- 2017-04-26 JP JP2017087530A patent/JP2017189167A/ja active Pending
-
2018
- 2018-04-27 US US15/965,382 patent/US11518984B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015500811A5 (enExample) | ||
| US11851493B2 (en) | Trispecific antagonists | |
| JP2014519830A5 (enExample) | ||
| JP2021191273A (ja) | 腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインを調製および使用する方法 | |
| JP2011502479A5 (enExample) | ||
| JP7683932B2 (ja) | ナチュラルキラー細胞を刺激するための組成物及び方法 | |
| JP2022523197A (ja) | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 | |
| JP2018512856A5 (enExample) | ||
| WO2019178364A2 (en) | Multifunctional molecules and uses thereof | |
| JP2017101068A5 (enExample) | ||
| AU2015299039A1 (en) | CD3 binding domain | |
| JP2017529326A5 (enExample) | ||
| HRP20240996T1 (hr) | Prefuzija rsv f proteina i njihova uporaba | |
| WO2010105573A1 (zh) | 抗血管新生融合蛋白 | |
| JP2017532045A5 (enExample) | ||
| JP2016513669A5 (enExample) | ||
| FI2968461T3 (fi) | Fuusioproteiineja, jotka käsittävät pdgf:ää ja vegf:ää sitovia osia, ja menetelmiä niiden käyttämiseksi | |
| JP2024028761A (ja) | 変異したＴＧＦβ１－ＲＩＩ細胞外ドメインおよび免疫グロブリン足場で構成される抗腫瘍アンタゴニスト | |
| ES2686968T3 (es) | Proteínas de fusión bifuncionales para inhibir la angiogénesis en el microambiente tumoral y para activar las respuestas inmunitarias adaptativas y los genes y usos de las mismas | |
| JP2015524413A5 (enExample) | ||
| JP2024084773A (ja) | Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体 | |
| JP2022511286A (ja) | Ｓｉｒｐアルファ系キメラタンパク質を含む併用療法 | |
| JP2020535811A5 (enExample) | ||
| JP2013529178A5 (enExample) | ||
| CN107223133A (zh) | 一种可溶的异质二聚t细胞受体及其制法和应用 |